

2018 Arrhythmia Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Arrhythmia Market

https://marketpublishers.com/r/2190EF885B5EN.html

Date: June 2018

Pages: 70

Price: US\$ 999.00 (Single User License)

ID: 2190EF885B5EN

Abstracts

Arrhythmia or cardiac dysrhythmia refers to abnormal rate of heart beats and effects around 6 million people in the US alone. More than 20% of these patients are hospitalized and 8-9% witness death. The pace of heart beat is irregular, or either more than the normal range (tachycardia) or slower than normal (bradycardia). Primary factors contributing to the Arrhythmia condition include diabetes, smoking, stress while symptoms include palpitations, short of breath etc.

To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Arrhythmia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Arrhythmia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Arrhythmia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.



Contents

1 TABLE OF CONTENTS

- 1.1 List of LIST OF FIGURES
- 1.2 List of Tables

2 ARRHYTHMIA PIPELINE ANALYSIS

- 2.1 Disease and Pipeline Overview
- 2.2 Arrhythmia Pipeline Snapshot
- 2.3 Arrhythmia Pipeline by Phase
- 2.4 Arrhythmia Pipeline by Company
- 2.5 Arrhythmia Pipeline by Mechanism of Action

3 ARRHYTHMIA- COMPANY WISE PIPELINE ANALYSIS

AETAS Pharma Co.,Ltd

Armgo Pharma, Inc.

Beijing CoSci Med-Tech Co.,Ltd

Gilead Sciences, Inc.

HUYA Bioscience International, LLC

InCarda Therapeutics, Inc.

LATITUDE Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc.

Numerate, Inc.

OMEICOS Therapeutics GmbH

Ono Pharmaceutical Co., Ltd.

Sanofi SA

Servier Laboratories Limited

Sign Path Pharma Inc

4 ARRHYTHMIA R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details

Therapeutic Candidate Name

Originator

Co-Developer/ License Partner

Orphan Drug Designation



Development Phase Mechanism of Action Current Status Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN ARRHYTHMIA PIPELINE

6 APPENDIX

- 6.1 About VPA Research
- 6.2 Sources and Research Methodology



List Of Figures

LIST OF FIGURES

Figure 1: Arrhythmia Pipeline by Phase, H2- 201	Figure 1: Arrh	ythmia	Pipeline I	bv Phase.	H2-	201	18
---	----------------	--------	------------	-----------	-----	-----	----

- Figure 2: Arrhythmia Pipeline by Companies, H2- 2018
- Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
- Figure 4: Arrhythmia Pipeline by Mechanism of Action, H2- 2018
- Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018



List Of Tables

LIST OF TABLES

Arrhythmia Pipeline by Phase, H2- 2018

Arrhythmia Pipeline by Companies, H2- 2018

Arrhythmia Pipeline by Mechanism of Action, H2- 2018

Table 1: AETAS Pharma Co., Ltd Arrhythmia Pipeline Drugs, H2-2018

Table 2: Armgo Pharma, Inc. Arrhythmia Pipeline Drugs, H2- 2018

Table 3: Beijing CoSci Med-Tech Co., Ltd Arrhythmia Pipeline Drugs, H2-2018

Table 4: Gilead Sciences, Inc. Arrhythmia Pipeline Drugs, H2-2018

Table 5: HUYA Bioscience International, LLC Arrhythmia Pipeline Drugs, H2-2018

Table 6: InCarda Therapeutics, Inc. Arrhythmia Pipeline Drugs, H2- 2018

Table 7: LATITUDE Pharmaceuticals Inc. Arrhythmia Pipeline Drugs, H2- 2018

Table 8: Milestone Pharmaceuticals Inc. Arrhythmia Pipeline Drugs, H2-2018

Table 9: Numerate, Inc. Arrhythmia Pipeline Drugs, H2-2018

Table 10: OMEICOS Therapeutics GmbH Arrhythmia Pipeline Drugs, H2- 2018

Table 11: Ono Pharmaceutical Co., Ltd. Arrhythmia Pipeline Drugs, H2-2018

Table 12: Sanofi SA Arrhythmia Pipeline Drugs, H2- 2018

Table 13: Servier Laboratories Limited Arrhythmia Pipeline Drugs, H2- 2018

Table 14: Sign Path Pharma Inc Arrhythmia Pipeline Drugs, H2- 2018



I would like to order

Product name: 2018 Arrhythmia Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical

Trials, Latest Developments in Arrhythmia Market

Product link: https://marketpublishers.com/r/2190EF885B5EN.html

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/2190EF885B5EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

